A prospective randomized control trial comparing medical and surgical treatment for early pregnancy failure.
A prospective randomized control trial was designed to assess the effectiveness of single dose, 800 microg misoprostol administered p.v. compared with surgical evacuation for the treatment of early pregnancy failure. A total of 80 women with a diagnosis of early pregnancy failure were randomized to study (vaginal misoprostol) and control (surgical curettage) groups. Success of treatment, side-effects as assessed during, immediately after and 10 days after treatment, and patient satisfaction were compared. Intravaginal misoprostol was successful in 82.5% (33 out of 40) of the patients. None of the control group patients required a repeat evacuation. The number of patients who experienced significant abdominal pain following treatment did not differ between the groups. The duration of pain was shorter in the control group; however, they required more analgesics during this short period. The number of patients with significant vaginal bleeding, the duration or severity of bleeding did not show any significant difference between the groups. All 33 patients in the study group who had successful treatment expressed satisfaction, whereas only 58% of the control group did so. In conclusion this randomized control study demonstrated the efficacy and safety of the administration of 800 microg of misoprostol p.v. for the management of early pregnancy failure.
Demetroulis
C
C
Department of Obstetrics and Gynaecology, Newham General Hospital, London, UK.
Saridogan
E
E
Kunde
D
D
Naftalin
A A
AA
D000027:Abortion, Incomplete / Q000188:drug therapy* / Q000601:surgery*; D000030:Abortion, Missed / Q000188:drug therapy* / Q000601:surgery*; D000282:Administration, Intravaginal; D004107:Dilatation and Curettage / Q000009:adverse effects; D005260:Female; D006801:Humans; D016595:Misoprostol / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D010120:Oxytocics / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D017060:Patient Satisfaction; D011247:Pregnancy; D011446:Prospective Studies
D010120:Oxytocics; D016595:Misoprostol